Mei-Cheng Wang
Research Subjects
Mei-Cheng Wang has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Kwun Chuen Gary Chan
Department of Biostatistics University of Washington Seattle Washington USA
4 shared publications - Anja Soldan
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
3 shared publications - Corinne Pettigrew
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
3 shared publications - Shanshan Li
Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21287, USA
3 shared publications - Sy Han Chiou
Department of Mathematical Sciences, University of Texas at Dallas, Richardson, Texas, USA
3 shared publications - Abhay Moghekar
Department of Neurology Johns Hopkins University School of Medicine Baltimore Maryland USA
2 shared publications
Latest Publications
- 19 November 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 109 (1) , 483-493
Modeling the age-specific incidence of mild cognitive impairment incorporating the time-varying relationship of Alzheimer's disease biomarkers over 28 years
Background: As life expectancy increases, the prevalence of mild cognitive impairment (MCI) due to Alzheimer's disease is expected to rise. Biomarkers from cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI), combined with age-specific modeling, may enhance understanding of the timing and risk factors of MCI onset. Objective: To estimate age-specific incidence rates of MCI onset and examine the impact of biomarkers and demographic factors on risk. Methods: We analyzed data from 307 cognitively unimpaired BIOCARD participants with one or more CSF and MRI measurements. To account for competing risk of death, we applied age-specific cumulative incidence functions and cause-specific Cox proportional hazard models. Time-varying biomarker values were incorporated to assess their influence on MCI risk. Results: The cumulative incidence rate of MCI onset estimated in age brackets from 50 to 80 was 2.33% at age 55, 5.03% at age 60, 12.38% at age 65, 17.91% at age 70, 28.84% at age 75, and 46.91% at age 80. APOE4 carriers had a significantly increased risk before age 70 (HR = 9.55, p = 0.005). Female APOE4 carriers showed a non-significant trend toward reduced risk compared to males (HR = 0.35, p = 0.127). Faster decline in entorhinal cortex volume (HR = 1.24, p = 0.028) and elevated p-tau 181 levels (HR = 1.51, p = 0.012) were both associated with increased MCI risk. Conclusions: This study presents age-specific incidence rates of MCI and highlights the age-dependent influence of genetic and biomarker risk factors. Incorporating time-varying biomarkers provides valuable insights into dynamic risk prediction for MCI onset.
- 19 November 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 109 (1) , 483-493
Modeling the age-specific incidence of mild cognitive impairment incorporating the time-varying relationship of Alzheimer's disease biomarkers over 28 years
Background: As life expectancy increases, the prevalence of mild cognitive impairment (MCI) due to Alzheimer's disease is expected to rise. Biomarkers from cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI), combined with age-specific modeling, may enhance understanding of the timing and risk factors of MCI onset. Objective: To estimate age-specific incidence rates of MCI onset and examine the impact of biomarkers and demographic factors on risk. Methods: We analyzed data from 307 cognitively unimpaired BIOCARD participants with one or more CSF and MRI measurements. To account for competing risk of death, we applied age-specific cumulative incidence functions and cause-specific Cox proportional hazard models. Time-varying biomarker values were incorporated to assess their influence on MCI risk. Results: The cumulative incidence rate of MCI onset estimated in age brackets from 50 to 80 was 2.33% at age 55, 5.03% at age 60, 12.38% at age 65, 17.91% at age 70, 28.84% at age 75, and 46.91% at age 80. APOE4 carriers had a significantly increased risk before age 70 (HR = 9.55, p = 0.005). Female APOE4 carriers showed a non-significant trend toward reduced risk compared to males (HR = 0.35, p = 0.127). Faster decline in entorhinal cortex volume (HR = 1.24, p = 0.028) and elevated p-tau 181 levels (HR = 1.51, p = 0.012) were both associated with increased MCI risk. Conclusions: This study presents age-specific incidence rates of MCI and highlights the age-dependent influence of genetic and biomarker risk factors. Incorporating time-varying biomarkers provides valuable insights into dynamic risk prediction for MCI onset.
- Open Access
- 21 November 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (22) , e029311
Joint Associations of Pregnancy Complications and Postpartum Maternal Renal Biomarkers With Severe Cardiovascular Morbidities: A US Racially and Ethnically Diverse Prospective Birth Cohort Study
Background: Pregnancy complications are risk factors for cardiovascular disease (CVD). Little is known about the role of renal biomarkers measured shortly after delivery, individually or in combination with pregnancy complications, in predicting subsequent severe maternal CVD. Methods and Results: This study included 566 mothers of diverse races and ethnicities from the Boston Birth cohort, enrolled at delivery and followed prospectively. Plasma creatinine and CysC (cystatin C) were measured 1 to 3 days after delivery. CVD during follow‐up was defined by physician diagnoses in electronic medical records. Associations of renal biomarkers and pregnancy complications with time‐to‐CVD events were assessed using Cox proportional hazards models. During an average of 10.3±3.2 years of follow‐up, 30 mothers developed 1 or more CVDs. Only a modest association was observed between creatinine and risk of CVD. In comparison, we found that per 0.1 mg/L increase of CysC was associated with a hazard ratio (HR) of 1.2 (95% CI, 1.1–1.4) for CVD after adjusting for covariates. Compared with those without preeclampsia and with normal CysC level (≤75th percentile), mothers with preeclampsia and elevated CysC (>75th percentile) had the highest risk of CVD (HR, 4.6 [95% CI, 1.7–17.7]), whereas mothers with preeclampsia only or with elevated CysC only did not have significantly increased CVD risk. Similar synergistic effects for CVD were observed between CysC and preterm delivery. Conclusions: In this sample of US, traditionally underrepresented multiracial and multiethnic high‐risk mothers, elevated maternal plasma CysC, independently and jointly with pregnancy complications, increased risk of CVD later in life. These findings warrant further investigation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03228875.
- 21 November 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (22) , e029311
Open AccessJoint Associations of Pregnancy Complications and Postpartum Maternal Renal Biomarkers With Severe Cardiovascular Morbidities: A US Racially and Ethnically Diverse Prospective Birth Cohort Study
Background: Pregnancy complications are risk factors for cardiovascular disease (CVD). Little is known about the role of renal biomarkers measured shortly after delivery, individually or in combination with pregnancy complications, in predicting subsequent severe maternal CVD. Methods and Results: This study included 566 mothers of diverse races and ethnicities from the Boston Birth cohort, enrolled at delivery and followed prospectively. Plasma creatinine and CysC (cystatin C) were measured 1 to 3 days after delivery. CVD during follow‐up was defined by physician diagnoses in electronic medical records. Associations of renal biomarkers and pregnancy complications with time‐to‐CVD events were assessed using Cox proportional hazards models. During an average of 10.3±3.2 years of follow‐up, 30 mothers developed 1 or more CVDs. Only a modest association was observed between creatinine and risk of CVD. In comparison, we found that per 0.1 mg/L increase of CysC was associated with a hazard ratio (HR) of 1.2 (95% CI, 1.1–1.4) for CVD after adjusting for covariates. Compared with those without preeclampsia and with normal CysC level (≤75th percentile), mothers with preeclampsia and elevated CysC (>75th percentile) had the highest risk of CVD (HR, 4.6 [95% CI, 1.7–17.7]), whereas mothers with preeclampsia only or with elevated CysC only did not have significantly increased CVD risk. Similar synergistic effects for CVD were observed between CysC and preterm delivery. Conclusions: In this sample of US, traditionally underrepresented multiracial and multiethnic high‐risk mothers, elevated maternal plasma CysC, independently and jointly with pregnancy complications, increased risk of CVD later in life. These findings warrant further investigation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03228875.
- Open Access
Weibull Racing Survival Analysis with Competing Events, Left Truncation, and Time-varying Covariates
We propose Bayesian nonparametric Weibull delegate racing (WDR) for survival analysis with competing events and achieve both model interpretability and flexibility. Utilizing a natural mechanism of surviving competing events, we assume a race among a potentially infinite number of sub-events. In doing this, WDR accommodates nonlinear covariate effects with no need of data transformation. Moreover, WDR is able to handle left truncation, time-varying covariates, different types of censoring, and missing event times or types. We develop an efficient MCMC algorithm based on Gibbs sampling for Bayesian inference and provide an \texttt{R} package. Synthetic data analysis and comparison with benchmark approaches demonstrate WDR's outstanding performance and parsimonious nonlinear modeling capacity. In addition, we analyze two real data sets and showcase advantages of WDR. Specifically, we study time to death of three types of lymphoma and show the potential of WDR in modeling nonlinear covariate effects and discovering new diseases. We also use WDR to investigate the age at onset of mild cognitive impairment and interpret the accelerating or decelerating effects of biomarkers on the progression of Alzheimer's disease.
Open AccessWeibull Racing Survival Analysis with Competing Events, Left Truncation, and Time-varying Covariates
We propose Bayesian nonparametric Weibull delegate racing (WDR) for survival analysis with competing events and achieve both model interpretability and flexibility. Utilizing a natural mechanism of surviving competing events, we assume a race among a potentially infinite number of sub-events. In doing this, WDR accommodates nonlinear covariate effects with no need of data transformation. Moreover, WDR is able to handle left truncation, time-varying covariates, different types of censoring, and missing event times or types. We develop an efficient MCMC algorithm based on Gibbs sampling for Bayesian inference and provide an \texttt{R} package. Synthetic data analysis and comparison with benchmark approaches demonstrate WDR's outstanding performance and parsimonious nonlinear modeling capacity. In addition, we analyze two real data sets and showcase advantages of WDR. Specifically, we study time to death of three types of lymphoma and show the potential of WDR in modeling nonlinear covariate effects and discovering new diseases. We also use WDR to investigate the age at onset of mild cognitive impairment and interpret the accelerating or decelerating effects of biomarkers on the progression of Alzheimer's disease.
- Open Access
- 10 April 2023
- Published by Wiley in Statistics in Medicine
- Vol. 42 (14) , 2394-2408
Simultaneous hypothesis testing for multiple competing risks in comparative clinical trials
Competing risks data are commonly encountered in randomized clinical trials or observational studies. Ignoring competing risks in survival analysis leads to biased risk estimates and improper conclusions. Often, one of the competing events is of primary interest and the rest competing events are handled as nuisances. These approaches can be inadequate when multiple competing events have important clinical interpretations and thus of equal interest. For example, in COVID-19 in-patient treatment trials, the outcomes of COVID-19 related hospitalization are either death or discharge from hospital, which have completely different clinical implications and are of equal interest, especially during the pandemic. In this paper we develop nonparametric estimation and simultaneous inferential methods for multiple cumulative incidence functions (CIFs) and corresponding restricted mean times. Based on Monte Carlo simulations and a data analysis of COVID-19 in-patient treatment clinical trial, we demonstrate that the proposed method provides global insights of the treatment effects across multiple endpoints.
- 10 April 2023
- Published by Wiley in Statistics in Medicine
- Vol. 42 (14) , 2394-2408
Open AccessSimultaneous hypothesis testing for multiple competing risks in comparative clinical trials
Competing risks data are commonly encountered in randomized clinical trials or observational studies. Ignoring competing risks in survival analysis leads to biased risk estimates and improper conclusions. Often, one of the competing events is of primary interest and the rest competing events are handled as nuisances. These approaches can be inadequate when multiple competing events have important clinical interpretations and thus of equal interest. For example, in COVID-19 in-patient treatment trials, the outcomes of COVID-19 related hospitalization are either death or discharge from hospital, which have completely different clinical implications and are of equal interest, especially during the pandemic. In this paper we develop nonparametric estimation and simultaneous inferential methods for multiple cumulative incidence functions (CIFs) and corresponding restricted mean times. Based on Monte Carlo simulations and a data analysis of COVID-19 in-patient treatment clinical trial, we demonstrate that the proposed method provides global insights of the treatment effects across multiple endpoints.
- Open Access
Joint associations of pregnancy complications and postpartum maternal renal biomarkers with severe cardiovascular morbidities: A US racially diverse prospective birth cohort study
Rationale & Objective: Pregnancy complications are risk factors for cardiovascular diseases (CVD). Little is known about the role of renal biomarkers measured shortly after delivery, individually or in combination with pregnancy complications, in predicting subsequent severe maternal CVD. Methods: This study included 576 mothers of diverse ethnicities from the Boston Birth cohort, enrolled at delivery and followed prospectively. Plasma creatinine and cystatin C were measured 1-3 days after delivery. CVD during follow-up was defined by physician diagnoses in electronic medical records. Associations of renal biomarkers and pregnancy complications with time-to-CVD events were assessed using Cox proportional hazards models. Results: During an average of 10.3±3.2 years of follow-up, 34 mothers developed one or more CVD events. Although no significant associations were found between creatinine and risk of CVD, per unit increase of cystatin C (CysC) was associated with a hazard ratio (HR) of 5.21 (95%CI = 1.49-18.2) for CVD. A borderline significant interactive effect was observed between elevated CysC (≥75th percentile) and preeclampsia. Compared to those without preeclampsia and with normal CysC level (th percentile), mothers with preeclampsia and elevated CysC had the highest risk of CVD (HR=3.8, 95%CI = 1.4-10.2), while mothers with preeclampsia only or with elevated CysC only did not have significantly increased CVD risk. Similar synergistic effects for CVD were observed between CysC and preterm delivery. Conclusions: In this sample of US, traditionally under-represented multi-ethnic high-risk mothers, elevated maternal plasma cystatin C and pregnancy complications synergistically increased risk of CVD later in life. These findings warrant further investigation. Clinical Perspectives: What is new? Maternal postpartum elevated levels of cystatin C are independently associated with higher risk of cardiovascular diseases (CVD) later in life. Maternal pregnancy complications coupled with postpartum elevated levels of cystatin C synergistically increased future risk of CVD. What are the clinical implications? These findings, if further confirmed, suggest that women with pregnancy complications and elevated postpartum cystatin C may be at particular high risk for CVD later in life compared to women without these risk factors.
Open AccessJoint associations of pregnancy complications and postpartum maternal renal biomarkers with severe cardiovascular morbidities: A US racially diverse prospective birth cohort study
Rationale & Objective: Pregnancy complications are risk factors for cardiovascular diseases (CVD). Little is known about the role of renal biomarkers measured shortly after delivery, individually or in combination with pregnancy complications, in predicting subsequent severe maternal CVD. Methods: This study included 576 mothers of diverse ethnicities from the Boston Birth cohort, enrolled at delivery and followed prospectively. Plasma creatinine and cystatin C were measured 1-3 days after delivery. CVD during follow-up was defined by physician diagnoses in electronic medical records. Associations of renal biomarkers and pregnancy complications with time-to-CVD events were assessed using Cox proportional hazards models. Results: During an average of 10.3±3.2 years of follow-up, 34 mothers developed one or more CVD events. Although no significant associations were found between creatinine and risk of CVD, per unit increase of cystatin C (CysC) was associated with a hazard ratio (HR) of 5.21 (95%CI = 1.49-18.2) for CVD. A borderline significant interactive effect was observed between elevated CysC (≥75th percentile) and preeclampsia. Compared to those without preeclampsia and with normal CysC level (th percentile), mothers with preeclampsia and elevated CysC had the highest risk of CVD (HR=3.8, 95%CI = 1.4-10.2), while mothers with preeclampsia only or with elevated CysC only did not have significantly increased CVD risk. Similar synergistic effects for CVD were observed between CysC and preterm delivery. Conclusions: In this sample of US, traditionally under-represented multi-ethnic high-risk mothers, elevated maternal plasma cystatin C and pregnancy complications synergistically increased risk of CVD later in life. These findings warrant further investigation. Clinical Perspectives: What is new? Maternal postpartum elevated levels of cystatin C are independently associated with higher risk of cardiovascular diseases (CVD) later in life. Maternal pregnancy complications coupled with postpartum elevated levels of cystatin C synergistically increased future risk of CVD. What are the clinical implications? These findings, if further confirmed, suggest that women with pregnancy complications and elevated postpartum cystatin C may be at particular high risk for CVD later in life compared to women without these risk factors.
- 11 October 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (15) , e1640-e1650
CSF Alzheimer Disease Biomarkers
Background and Objectives This study aimed to examine whether baseline CSF measures of Alzheimer disease (AD)–related pathology are associated with the time to onset of mild cognitive impairment (MCI) and whether these associations differ by age, sex, Apolipoprotein E (ApoE4) status, and proximal (≤7 years) vs distal (>7 years) time to symptom onset. Methods Measures of amyloid (Aβ1-42 and Aβ1-40), phospho-tau (ptau181), and total tau (t-tau) were determined from CSF samples obtained at baseline from participants in an ongoing longitudinal project, known as the Biomarkers for Older Controls at Risk for Alzheimer Disease study (BIOCARD) study. The fully automated, Lumipulse G immunoassay was used to analyze the specimens. Cox regression models were used to examine the relationship of baseline biomarker levels with time to symptom onset of MCI and interactions with age, sex, and ApoE allelic status in subjects who progressed from normal cognition to MCI. Results Analyses included 273 participants from the BIOCARD cohort, who were cognitively normal and predominantly middle-aged at baseline, and have been followed for an average of 16 years (max = 23.6). During follow-up, 94 progressed to MCI (median time to symptom onset = 6.9 years). In Cox regression models, elevated ptau181 and t-tau levels were associated with time to MCI symptom onset if it occurred within 7 years of baseline (HR 1.386 and 1.329; p = 0.009 and 0.017, respectively), while a lower Aβ42/Aβ40 ratio was associated with symptom onset if it occurred >7 years from baseline (HR 0.596, p = 0.003). There were also significant 3-way CSF × age × sex interactions for ptau181 and Aβ42/Aβ40, with follow-up analyses indicating that associations between these biomarkers and progression to MCI were stronger among men than among women, but this difference between sexes diminished with increasing age. Discussion The lengthy follow-up of BIOCARD participants permitted an examination of time-varying associations between CSF AD biomarkers with MCI symptom onset and the influence of sex, baseline age, and ApoE4 genotype on these associations. These factors may inform clinical trial enrollment strategies, or trial duration and outcomes, which may use these measures as surrogate markers of treatment response.
- 11 October 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (15) , e1640-e1650
CSF Alzheimer Disease Biomarkers
Background and Objectives This study aimed to examine whether baseline CSF measures of Alzheimer disease (AD)–related pathology are associated with the time to onset of mild cognitive impairment (MCI) and whether these associations differ by age, sex, Apolipoprotein E (ApoE4) status, and proximal (≤7 years) vs distal (>7 years) time to symptom onset. Methods Measures of amyloid (Aβ1-42 and Aβ1-40), phospho-tau (ptau181), and total tau (t-tau) were determined from CSF samples obtained at baseline from participants in an ongoing longitudinal project, known as the Biomarkers for Older Controls at Risk for Alzheimer Disease study (BIOCARD) study. The fully automated, Lumipulse G immunoassay was used to analyze the specimens. Cox regression models were used to examine the relationship of baseline biomarker levels with time to symptom onset of MCI and interactions with age, sex, and ApoE allelic status in subjects who progressed from normal cognition to MCI. Results Analyses included 273 participants from the BIOCARD cohort, who were cognitively normal and predominantly middle-aged at baseline, and have been followed for an average of 16 years (max = 23.6). During follow-up, 94 progressed to MCI (median time to symptom onset = 6.9 years). In Cox regression models, elevated ptau181 and t-tau levels were associated with time to MCI symptom onset if it occurred within 7 years of baseline (HR 1.386 and 1.329; p = 0.009 and 0.017, respectively), while a lower Aβ42/Aβ40 ratio was associated with symptom onset if it occurred >7 years from baseline (HR 0.596, p = 0.003). There were also significant 3-way CSF × age × sex interactions for ptau181 and Aβ42/Aβ40, with follow-up analyses indicating that associations between these biomarkers and progression to MCI were stronger among men than among women, but this difference between sexes diminished with increasing age. Discussion The lengthy follow-up of BIOCARD participants permitted an examination of time-varying associations between CSF AD biomarkers with MCI symptom onset and the influence of sex, baseline age, and ApoE4 genotype on these associations. These factors may inform clinical trial enrollment strategies, or trial duration and outcomes, which may use these measures as surrogate markers of treatment response.
- 26 August 2022
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 79 (3) , 1635-1645
Joint Inference for Competing Risks Data Using Multiple Endpoints
Competing risks data are commonly encountered in randomized clinical trials and observational studies. This paper considers the situation where the ending statuses of competing events have different clinical interpretations and/or are of simultaneous interest. In clinical trials, often more than one competing event has meaningful clinical interpretations even though the trial effects of different events could be different or even opposite to each other. In this paper, we develop estimation procedures and inferential properties for the joint use of multiple cumulative incidence functions (CIFs). Additionally, by incorporating longitudinal marker information, we develop estimation and inference procedures for weighted CIFs and related metrics. The proposed methods are applied to a COVID-19 in-patient treatment clinical trial, where the outcomes of COVID-19 hospitalization are either death or discharge from the hospital, two competing events with completely different clinical implications.
- 26 August 2022
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 79 (3) , 1635-1645
Joint Inference for Competing Risks Data Using Multiple Endpoints
Competing risks data are commonly encountered in randomized clinical trials and observational studies. This paper considers the situation where the ending statuses of competing events have different clinical interpretations and/or are of simultaneous interest. In clinical trials, often more than one competing event has meaningful clinical interpretations even though the trial effects of different events could be different or even opposite to each other. In this paper, we develop estimation procedures and inferential properties for the joint use of multiple cumulative incidence functions (CIFs). Additionally, by incorporating longitudinal marker information, we develop estimation and inference procedures for weighted CIFs and related metrics. The proposed methods are applied to a COVID-19 in-patient treatment clinical trial, where the outcomes of COVID-19 hospitalization are either death or discharge from the hospital, two competing events with completely different clinical implications.
- 24 June 2022
- Published by Springer Nature in Lifetime Data Analysis
- Vol. 28 (4) , 659-674
Bias correction via outcome reassignment for cross-sectional data with binary disease outcome
Cross-sectionally sampled data with binary disease outcome are commonly analyzed in observational studies to identify the relationship between covariates and disease outcome. A cross-sectional population is defined as a population of living individuals at the sampling or observational time. It is generally understood that binary disease outcome from cross-sectional data contains less information than longitudinally collected time-to-event data, but there is insufficient understanding as to whether bias can possibly exist in cross-sectional data and how the bias is related to the population risk of interest. Wang and Yang (2021) presented the complexity and bias in cross-sectional data with binary disease outcome with detailed analytical explorations into the data structure. As the distribution of the cross-sectional binary outcome is quite different from the population risk distribution, bias can arise when using cross-sectional data analysis to draw inference for population risk. In this paper we argue that the commonly adopted age-specific risk probability is biased for the estimation of population risk and propose an outcome reassignment approach which reassigns a portion of the observed binary outcome, 0 or 1, to the other disease category. A sign test and a semiparametric pseudo-likelihood method are developed for analyzing cross-sectional data using the OR approach. Simulations and an analysis based on Alzheimer’s Disease data are presented to illustrate the proposed methods.
- 24 June 2022
- Published by Springer Nature in Lifetime Data Analysis
- Vol. 28 (4) , 659-674
Bias correction via outcome reassignment for cross-sectional data with binary disease outcome
Cross-sectionally sampled data with binary disease outcome are commonly analyzed in observational studies to identify the relationship between covariates and disease outcome. A cross-sectional population is defined as a population of living individuals at the sampling or observational time. It is generally understood that binary disease outcome from cross-sectional data contains less information than longitudinally collected time-to-event data, but there is insufficient understanding as to whether bias can possibly exist in cross-sectional data and how the bias is related to the population risk of interest. Wang and Yang (2021) presented the complexity and bias in cross-sectional data with binary disease outcome with detailed analytical explorations into the data structure. As the distribution of the cross-sectional binary outcome is quite different from the population risk distribution, bias can arise when using cross-sectional data analysis to draw inference for population risk. In this paper we argue that the commonly adopted age-specific risk probability is biased for the estimation of population risk and propose an outcome reassignment approach which reassigns a portion of the observed binary outcome, 0 or 1, to the other disease category. A sign test and a semiparametric pseudo-likelihood method are developed for analyzing cross-sectional data using the OR approach. Simulations and an analysis based on Alzheimer’s Disease data are presented to illustrate the proposed methods.
- Open Access
- 28 June 2021
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 31 (12) , 5637-5651
Association of Lifestyle Activities with Functional Brain Connectivity and Relationship to Cognitive Decline among Older Adults
This study examines the relationship of engagement in different lifestyle activities to connectivity in large-scale functional brain networks, and whether network connectivity modifies cognitive decline, independent of brain amyloid levels. Participants (N = 153, mean age = 69 years, including N = 126 with amyloid imaging) were cognitively normal when they completed resting-state functional magnetic resonance imaging, a lifestyle activity questionnaire, and cognitive testing. They were followed with annual cognitive tests up to 5 years (mean = 3.3 years). Linear regressions showed positive relationships between cognitive activity engagement and connectivity within the dorsal attention network, and between physical activity levels and connectivity within the default-mode, limbic, and frontoparietal control networks, and global within-network connectivity. Additionally, higher cognitive and physical activity levels were independently associated with higher network modularity, a measure of functional network specialization. These associations were largely independent of APOE4 genotype, amyloid burden, global brain atrophy, vascular risk, and level of cognitive reserve. Moreover, higher connectivity in the dorsal attention, default-mode, and limbic networks, and greater global connectivity and modularity were associated with reduced cognitive decline, independent of APOE4 genotype and amyloid burden. These findings suggest that changes in functional brain connectivity may be one mechanism by which lifestyle activity engagement reduces cognitive decline.
- 28 June 2021
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 31 (12) , 5637-5651
Open AccessAssociation of Lifestyle Activities with Functional Brain Connectivity and Relationship to Cognitive Decline among Older Adults
This study examines the relationship of engagement in different lifestyle activities to connectivity in large-scale functional brain networks, and whether network connectivity modifies cognitive decline, independent of brain amyloid levels. Participants (N = 153, mean age = 69 years, including N = 126 with amyloid imaging) were cognitively normal when they completed resting-state functional magnetic resonance imaging, a lifestyle activity questionnaire, and cognitive testing. They were followed with annual cognitive tests up to 5 years (mean = 3.3 years). Linear regressions showed positive relationships between cognitive activity engagement and connectivity within the dorsal attention network, and between physical activity levels and connectivity within the default-mode, limbic, and frontoparietal control networks, and global within-network connectivity. Additionally, higher cognitive and physical activity levels were independently associated with higher network modularity, a measure of functional network specialization. These associations were largely independent of APOE4 genotype, amyloid burden, global brain atrophy, vascular risk, and level of cognitive reserve. Moreover, higher connectivity in the dorsal attention, default-mode, and limbic networks, and greater global connectivity and modularity were associated with reduced cognitive decline, independent of APOE4 genotype and amyloid burden. These findings suggest that changes in functional brain connectivity may be one mechanism by which lifestyle activity engagement reduces cognitive decline.
- Open Access
- 1 June 2021
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (6) , 777-785
Development of Severe COVID-19 Adaptive Risk Predictor (SCARP), a Calculator to Predict Severe Disease or Death in Hospitalized Patients With COVID-19
Predicting the clinical trajectory of individual patients hospitalized with COVID-19 is necessary to inform clinical care. This article describes the development of an online tool to predict severe... Visual Development of Severe COVID-19 Adaptive Risk Predictor. Predicting the clinical trajectory of individual patients hospitalized with COVID-19 is necessary to inform clinical care. Th... Background: Predicting the clinical trajectory of individual patients hospitalized with coronavirus disease 2019 (COVID-19) is challenging but necessary to inform clinical care. The majority of COV...
- 1 June 2021
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (6) , 777-785
Open AccessDevelopment of Severe COVID-19 Adaptive Risk Predictor (SCARP), a Calculator to Predict Severe Disease or Death in Hospitalized Patients With COVID-19
Predicting the clinical trajectory of individual patients hospitalized with COVID-19 is necessary to inform clinical care. This article describes the development of an online tool to predict severe... Visual Development of Severe COVID-19 Adaptive Risk Predictor. Predicting the clinical trajectory of individual patients hospitalized with COVID-19 is necessary to inform clinical care. Th... Background: Predicting the clinical trajectory of individual patients hospitalized with coronavirus disease 2019 (COVID-19) is challenging but necessary to inform clinical care. The majority of COV...